Clinical Trials on Lymphoid Malignancies in Switzerland

Total 225 results

University of Zurich

Unknown

Lymphoma in the Orbit

Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

Lymphoma, Mucosa-Associated Lymphoid Tissue

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Terminated

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

Lymphoma, Mucosa-Associated Lymphoid Tissue

Switzerland
Thomas Zilli
University Hospital, Geneva

Recruiting

Total Marrow Irradiation With Volumetric Arc Therapy for Patients Unfit for a 12 Gy TBI

Haematological Malignancy

Switzerland
Swiss Pediatric Oncology Group
ALL SCTped Forum

Recruiting

ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

Acute Lymphoblastic Leukemia

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma

Splenic Marginal Zone Lymphoma

Switzerland
Novartis Pharmaceuticals

Completed

A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies

Hematological Malignancies

Germany, Switzerland, France
International Extranodal Lymphoma Study Group (IELSG)

Completed

Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

Lymphoma, B Cell

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

Lymphoma, B Cell

Switzerland
University Hospital, Geneva

Active, not recruiting

A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma (FRILLY)

Aggressive B-Cell Non-Hodgkin Lymphoma

Switzerland
Luzerner Kantonsspital

Recruiting

Prevalence of FID and QoL in Patients With Oncological and With Haematological Malignancies

Functional Iron Deficiency

Switzerland
Prelude Therapeutics
BeiGene

Recruiting

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies

T-cell Lymphoma | Mantle Cell Lymphoma (MCL) | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Richter's Syndrome | Aggressive B-Cell Non-Hodgkin's Lymphoma | Aggressive B-Cell NHL

United States, Canada, Korea, Republic of, Australia, France, Poland, Italy, Germany, Switzerland, United Kingdom
National Cancer Institute (NCI)

Completed

Raltitrexed in Treating Children With Refractory Acute Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia

Switzerland
University Hospital Inselspital, Berne

Completed

Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies (LUNCH1)

Colitis | AML | Mucositis

Switzerland
Mundipharma Research Limited

Active, not recruiting

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Multiple Myeloma | Hodgkin's Lymphoma | Hematological Malignancies | Cutaneous T Cell Lymphoma

France, United States, Netherlands, Spain, Switzerland, Germany, Italy
ImmunoGen, Inc.

Completed

IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States, Switzerland
European Organisation for Research and Treatment...
Mallinckrodt

Withdrawn

Study of Photopheresis in the Treatment of Erythrodermic MF and SS (PROMPT)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides/Sezary Syndrome

Switzerland
EMD Serono

Terminated

A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

Haematological Malignancies

Italy, United States, Switzerland, Belgium, Germany
University Hospital, Basel, Switzerland

Completed

NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Lymphoma | Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Neuroblastoma | Rhabdomyosarcoma

Switzerland, Germany
University Hospital, Basel, Switzerland
University Hospital, Geneva; University Hospital, Zürich

Completed

Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT

Myeloid Leukemia | Precursor Myeloid Neoplasms | Lymphoid Neoplasms

Switzerland
AbbVie
Roche-Genentech

Completed

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Non-Hodgkin's Lymphoma | Neuroblastoma | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Malignancies

United States, Australia, Canada, France, Germany, Netherlands, Switzerland, United Kingdom
University Hospital Inselspital, Berne
Hanusk Krankenhaus Wien

Completed

A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) (BEB)

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell

Switzerland, Austria
Oncology Institute of Southern Switzerland

Recruiting

Liquid Biopsy in Mature B-cell Tumors

Mature B-Cell Neoplasm

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

Lymphoma, Mucosa-Associated Lymphoid Tissue

United Kingdom, France, Italy, Switzerland, Spain, Belgium
Swiss Group for Clinical Cancer Research

Terminated

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Non-Hodgkin Lymphoma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Follicular Lymphoma

Switzerland
University Hospital Erlangen

Completed

Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia

Lymphoma | Leukemia

Germany, Switzerland
University of Zurich

Completed

T-VEC in Non-melanoma Skin Cancer (20139157 T-VEC)

Merkel Cell Carcinoma | Basal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin Cancer | Cutaneous Lymphoma

Switzerland
University Hospital Inselspital, Berne

Active, not recruiting

CD34+ Selected ASCT for Aggressive Lymphomas (SAAL)

Malignant Non-Hodgkin Lymphomas

Switzerland
Merck KGaA, Darmstadt, Germany

Completed

EMD 521873 in Advanced Solid Tumors, MTD Finding

Non-Hodgkin Lymphoma

Germany, Switzerland
Onxeo

Completed

A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma

Cutaneous T-cell Lymphoma

Austria, France, Germany, Switzerland
European Organisation for Research and Treatment...
Hoffmann-La Roche

Terminated

PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) (PARCT)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides/Sezary Syndrome

Spain, Switzerland
Oncology Institute of Southern Switzerland
Azienda Ospedaliero Universitaria Maggiore della Carita; Arcispedale Santa... and other collaborators

Active, not recruiting

Personalized Risk Stratification Model of Follicular Lymphoma Patients

Follicular Lymphoma

Italy, Switzerland
Cristiana Sessa

Completed

Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma (IOSI-LND-001)

B-cell Lymphoma Refractory

Switzerland
MEI Pharma, Inc.

Terminated

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone B Cell Lymphoma | High Grade Non-Hodgkin's Lymphoma

United States, Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)

Marginal Zone B-cell Lymphoma

Italy, Switzerland, Austria
Celgene
Juno

Withdrawn

A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia (ORBIT)

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Belgium, France, Spain, Italy, Germany, Switzerland, United Kingdom
Kartos Therapeutics, Inc.

Recruiting

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

Belgium, Korea, Republic of, United States, United Kingdom, Italy, Switzerland, Australia, France, Poland, Portugal, Czechia
Swiss Group for Clinical Cancer Research

Completed

Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma

Lymphoma

Switzerland
Centre Hospitalier Universitaire Vaudois

Unknown

Breakthrough Invasive Mold Infections Under Posaconazole Prophylaxis (BIMI) (BIMI)

Hematologic Diseases | Hematologic Malignancy | Invasive Mold Infections | Breakthrough Invasive Mold Infections

Switzerland, Austria, Germany
Insel Gruppe AG, University Hospital Bern
Mundipharma Medical Company

Suspended

Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas (BAL)

Lymphoma

Switzerland
Lymphoma Study Association
Fondation ARC

Terminated

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Lymphoma, Large-Cell, Diffuse

France, Switzerland, Belgium
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Study of Acalabrutinib and Tafasitamab in MZL Patients

Marginal Zone Lymphoma

Italy, Switzerland, Austria
Ethical Oncology Science

Completed

Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas

Lymphoma, Non-Hodgkin | Solid Tumors

Switzerland, Italy
Novartis Pharmaceuticals

Terminated

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Advanced Malignancies

Taiwan, Netherlands, Italy, Korea, Republic of, Japan, United States, Switzerland, Canada, Singapore
Oncology Institute of Southern Switzerland
Ente Ospedaliero Cantonale, Bellinzona; Istituto Cantonale di Patologia

Recruiting

Tumor Molecular Profiling in Early Phase Clinical Trials

Lymphoma | Advanced Solid Tumor

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Recruiting

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Nodal Marginal Zone Lymphoma

United States, Switzerland, Armenia, France, Italy
Swiss Group for Clinical Cancer Research

Completed

Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma

Lymphoma

Switzerland
University of Zurich

Completed

Determination of Blood Tumor Cells

Leukemia, Lymphocytic, Chronic, B-Cell | Abnormalities Cell Epithelial

Switzerland
University Hospital Muenster
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma (LBL 2018)

Lymphoblastic Lymphoma, Childhood

Spain, Austria, Denmark, Finland, Germany, Belgium, Switzerland, China, Czechia, France, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Sweden

Clinical Trials on Lymphoid Malignancies in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations